Noopept


Overview

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a Russian-developed nootropic, structurally related to the racetam family but active at doses a hundred times smaller. It is one of the few nootropics with actual clinical trials — in Russia, where it is an approved medication for cognitive impairment.

In the West it occupies the grey zone of unapproved but widely used cognitive enhancers.

How It Works

Noopept modulates glutamatergic transmission at AMPA receptors and increases expression of BDNF and NGF — neurotrophins essential for learning, memory and neuronal survival. It also shows antioxidant and anti-inflammatory effects in brain tissue.

Fast and slow effects

Users report acute effects on clarity and verbal fluency within an hour, while the neurotrophin-mediated benefits are thought to build over weeks of consistent use. Russian clinical trials in mild cognitive impairment ran for 8-12 weeks and showed modest but real improvements.

Key Benefits

Memory and learning — the core claim, with Russian clinical trial support in impaired populations.

Verbal fluency and clarity — the most commonly reported acute subjective effect.

Neuroprotection — BDNF/NGF upregulation and antioxidant effects in animal models.

Anxiolytic component — mild calming effects reported, unusual among stimulating nootropics.

Side Effects & Considerations

Noopept is well tolerated: occasional headache (the classic cholinergic-signaling headache, sometimes addressed with a choline source), irritability at high doses, and rare blood pressure increases.

Evidence calibration

The trials that exist are Russian, small, and in cognitively impaired patients — whether it does anything measurable in healthy young brains is genuinely unknown. Western regulatory bodies have not evaluated it. It is cheap, widely available, and probably low-risk, but expectations should be modest: this is a subtle tool, not a Limitless pill.

Dosage protocols

Protocol Dosage Frequency Duration Notes
Standard 10-30 mg 1-2 times daily 8-12 weeks per Russian trial design Sublingual administration is popular for faster onset. Take breaks between cycles.

Warnings

Not approved outside Russia. Evidence in healthy people is weak. Occasional headaches — some users add a choline source.